Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6194 in Adult Participants With Systemic Lupus Erythematosus
NCT06161116Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of PT101 in systemic lupus erythematosus (SLE) (4 arms), sponsored by Merck & Co. Primary endpoints: Systemic Lupus Erythematosus Responder Index Response at 28 weeks, Adverse Events at 16 months and 1 more. Started Dec 2023; status: terminated.
02
Drugs
PT101
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06161116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161116.